Next Generation RNA Therapeutics Market Size is Anticipated to Reach USD 2.7 billion by 2035

According to a recently published report by Roots Analysis, rapid advancements in RNA delivery technologies, increasing investments in RNA-based therapeutics and expanding pipeline of next-generation RNA medicines and vaccines, is driving significant growth in next generation RNA therapeutics market.

Global Next Generation RNA Therapeutics Market Overview

The global next generation RNA therapeutics market is expected to reach around USD 2.7 billion by 2035, growing at a CAGR of 63.1% during the forecast period till 2035.

Traditional RNA-based therapies are known to be associated with various stability and delivery-related challenges. This has prompted industry stakeholders to modify such therapies to develop next generation therapies possessing structural stability, expression specificity and non-immunogenic nature along with the ability to target a myriad of therapeutic indications. Moreover, the self-replicating characteristics of such therapies confer prolonged therapeutic effects at relatively low and less frequent doses of administration. In addition, the advancements in the development of novel technologies for the development and delivery of such therapies have escalated the interest of industry stakeholders in developing enhanced and modified RNA-based therapies. Considering the vast potential and ability to circumvent challenges associated with the conventional therapeutic modalities, the next generation RNA therapies domain is anticipated to evolve rapidly to become the next big therapeutic segment in the coming decade.

Browse 150+ figures and ~160 market data tables spread across ~240 slides and detailed Table of Content on “Global Next Generation RNA Therapeutics Market”, till 2035 by Type of Modality (Therapeutics and Vaccines), Type of Molecule (circRNA, sacRNA and saRNA), Target Indication (Advanced Solid Tumors, Hepatocellular Carcinoma, Inherited Bone Marrow Failure Syndromes, Radiation-Induced Xerostomia and Hyposalivation, and Seasonal Influenza), Route of Administration (Intraductal Route, Intramuscular Route, Intratumoral Route and Intravenous Route), Geographical Regions (North America, Europe and Asia-Pacific) and Leading Players https://www.rootsanalysis.com/reports/rna-therapeutics-market.html

Market Drivers

Several factors are propelling the growth of global next generation RNA therapeutics market. One of the primary reason is the growing prevalence of chronic diseases worldwide which is fueling the demand for targeted and effective therapeutic approaches. Additionally, the increasing focus of the healthcare providers towards personalized medicine has led to the development of next generation RNA therapeutics and vaccines, possessing target specificity and self-replicability. Further, the advent of novel technologies for the development and delivery of such modalities is driving the adoption of such therapies. These market drivers collectively shape the evolving landscape of the global next generation RNA therapeutics market.

Market Restraints

While the global next generation RNA therapeutics market is experiencing substantial growth, there are certain restraints that can hinder the growth of this industry. One of the primary challenges is navigating the complex regulatory requirements associated with the development and approval of novel RNA modalities, particularly those involving new delivery systems, RNA constructs, and combination approaches. Further, challenges associated with RNA stability, immunogenicity, tissue-specific delivery, cellular uptake, and durability of therapeutic effects can increase development complexity and costs. In addition, the limited clinical validation of several next-generation RNA approaches and the high attrition rate observed across early- and late-stage development programs remain significant barriers to commercialization.

Growth Factors

Despite the aforementioned restraints, several growth factors continue to drive the global next generation RNA therapeutics market forward. One notable factor is the growing demand for efficient and targeted therapies that can be administered at low dose frequency and strengths. Additionally, continuous evolution and innovation in research and development of RNA therapeutics and vaccines is another market driver propelling the growth of the market during the forecast period. Moreover, the growing global burden imposed by chronic diseases has stimulated the interest of stakeholders engaged in this domain. Driven by their clinical potential to specifically target and treat various disease indications, the next generation RNA therapeutics and vaccines have gained significant traction and are anticipated to revolutionize the healthcare and medical sector.

Global Next Generation RNA Therapeutics Market Segments

Based on the type of modality, the market is segmented into therapeutics and vaccines.

• The therapeutics segment is likely to lead the next generation RNA therapeutics market, capturing the largest revenue share of more than 80% in 2035.
• The therapeutics segment is anticipated to grow at a higher CAGR of 57.4%, during the forecast period.

Based on the type of molecule, the market is segmented into circRNA, sacRNA and saRNA.

• The saRNA segment is expected to lead the next generation RNA therapeutics market, capturing the largest revenue share of around 60% in 2035.
• The saRNA segment is anticipated to grow at a higher CAGR of 73.6%, during the forecast period.

Based on the target indication, the market is segmented into advanced solid tumors, hepatocellular carcinoma, inherited bone marrow failure syndromes, radiation-induced xerostomia and hyposalivation, and seasonal influenza.

• The advanced solid tumors segment is likely to lead the next generation RNA therapeutics market, capturing the largest revenue share of around 35% in the current year.
• The inherited bone marrow failure syndromes segment is anticipated to grow at a higher CAGR of 75.5%, during the forecast period.

Based on the route of administration, the market is segmented into intraductal route, intramuscular route, intratumoral route and intravenous route.

• The intratumoral route segment is anticipated to lead the next generation RNA therapeutics market, capturing the largest revenue share of around 35% in the current year.
• The intraductal route segment is anticipated to grow at a higher CAGR of 70.2%, during the forecast period.

Based on geographical regions, the market is segmented into North America, Europe and Asia-Pacific.

• North America is likely to dominate the next generation RNA therapeutics market, accounting for the largest revenue share of more than 65% in 2035.
• The next generation RNA therapeutics market in Europe is anticipated to demonstrate a higher growth rate of 85.9% during the forecast period.

Key Companies Profiled

The global next generation RNA therapeutics market report also includes detailed profiles of developers (listed below) that are engaged in the next generation RNA therapeutics domain:

• AlphaVax
• Arcturus Therapeutics
• BioNTech
• HDT Bio
• MiNA Therapeutics
• VLP Therapeutics

You Can Download Free Sample PDF Copy of This Report At:  https://www.rootsanalysis.com/reports/rna-therapeutics-market/request-sample.html

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

Contact Details

Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com